Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel cytokine-driven hyper-inflammation, thrombotic microangiopathy and NET-driven immunothrombosis, thereby leading to multi-organ failure. Complement therapeut...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Immunol
Main Authors: Mastellos, Dimitrios C., Pires da Silva, Bruno G.P., Fonseca, Benedito A.L., Fonseca, Natasha P., Auxiliadora-Martins, Maria, Mastaglio, Sara, Ruggeri, Annalisa, Sironi, Marina, Radermacher, Peter, Chrysanthopoulou, Akrivi, Skendros, Panagiotis, Ritis, Konstantinos, Manfra, Ilenia, Iacobelli, Simona, Huber-Lang, Markus, Nilsson, Bo, Yancopoulou, Despina, Connolly, E. Sander, Garlanda, Cecilia, Ciceri, Fabio, Risitano, Antonio M., Calado, Rodrigo T., Lambris, John D.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Inc. 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7501834/
https://ncbi.nlm.nih.gov/pubmed/32961333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2020.108598
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados